QUANTIFY RESEARCH is a global partner to the pharmaceutical industry in close partnership with academia, patients, public institutions & clinical experts.
Real-world evidence & analytics
Quantify is the leading provider of RWE generated from the world-renouned Nordic data. Through our local presence, expert staff, institutional know-how and more than 10 years’ hands-on experience with the Nordic data, we offer an unparalleled ability to advise and execute Nordic RWE studies with local and global applications. Quantify has a successful track record of advising clients on securing Nordic ethical approval, data access, and optimizing analysis for commercial or regulatory purposes. We also offer RWE services in the EU, UK, and US.
Modelling, Access & Strategy
Quantify is a global provider of health economic evidence and a specialist provider of Nordic market access services including economic models, reimbursement dossiers, and strategic advice. Our experience and expertise ensures an optimized, streamlined market access process across the Nordics. For non-technical stakeholders, Quantify also develops value tools and visualisation dashboards to enhance communication. Our expert staff include ex-payers, ex-pharma, modelling experts, and experienced project managers.
Evidence review & synthesis
Quantify has long standing experience reviewing, interpreting and communicating evidence as part of targeted or systematic literature reviews (SLR). Our team ensures these activities are done systematically, with a focus on usability, to support knowledge management and commercialization activities. QUANTIFY is experienced in summarizing the results of this work through meta-analyses and narrative reviews. Our team consists of 50% PhDs and integrated AI solutions to provide our clients with the very best services.
Press
Hot off the press!
This month, Quantify Research’s Emilie Toresson Grip, Helena Skröder Löveborn and Oskar Ström published a study in Diabetes Care, using a uniquely collected NAFLD dataset (“HERALD”).
Using HERALD, the study showed that having or acquiring additional traits of metabolic syndromes increased the rate of progression to major adverse liver outcomes (MALO) in patients with T2D.
This information may be used to inform screening programs for MALO.
Read the full article here: […]
📣 FDA Approves rezdiffra, the first treatment for Nash/Mash📣
About a week ago, FDA approved the very first treatment for patients with liver fibrosis caused by fatty liver disease.
Rezdiffra (resmetirom) is now approved for treatment of adults with noncirrhotic non-alcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), to be used along with diet and exercise.
While this is a significant milestone in the research area of NAFLD/NASH, many additional steps remain for all stakeholders in the field […]
Welcome Morten Johnsen!
We are very excited to introduce our latest recruit to the Danish team!
Morten Johnsen recently joined us following the completion of his Masters in Quantitative Biology and Disease Modelling from DTU – Technical University of Denmark and a position as Student Data Analyst at Amager og Hvidovre Hospital.
“I’m thrilled to be joining Quantify Research […]
Curious about Danish real-world data? 🔍
Here are some of the things that makes our data unique:
1. Fast access to comprehensive data
In January 2024, the processing time at the Danish Health Data Authority decreased to just 34.9 days, providing swift access to a wealth of national-level data.
2. Rich clinical quality databases
Denmark boasts 80 nationwide clinical quality databases, offering invaluable
insights beyond administrative registries.
These databases include detailed information on symptoms, clinical verifications, imaging, prognostic parameters, and lifestyle […]